Page 69 - 2021_02-Haematologica-web

ASCT for progressive SSc
6.Hao Y, Hudson M, Baron M, et al. Early mortality in a multinational systemic sclero- sis inception cohort. Arthritis Rheumatol. 2017;69(5):1067-1077.
7.Steen VD, Medsger TA Jr, Rodnan GP. D- penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analy- sis. Ann Intern Med. 1982;97(5):652-659.
8. Steen VD, Medsger TA, Jr. The value of the Health Assessment Questionnaire and spe- cial patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997;40(11):1984- 1991.
9.Herrick AL, Pan X, Peytrignet S, et al. Treatment outcome in early diffuse cuta- neous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017;76(7):1207-1218.
10. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339.
11. Farge D, Marolleau JP, Zohar S, et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclero- sis: early results from a French multicentre phase I-II study. Br J Haematol. 2002;119 (3):726-739.
12.Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell trans- plantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010;95(2):284-292.
13. Henes JC, Schmalzing M, Vogel W, et al. Optimization of autologous stem cell trans- plantation for systemic sclerosis -- a single- center longterm experience in 26 patients with severe organ manifestations. J Rheumatol. 2012;39(2):269-275.
14. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for sys- temic sclerosis (ASSIST): an open-label, ran- domised phase 2 trial. Lancet. 2011;378 (9790):498-506.
15.van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell trans- plantation vs intravenous pulse cyclophos- phamide in diffuse cutaneous systemic scle- rosis: a randomized clinical trial. JAMA. 2014;311(24):2490-2498.
16. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35-47.
17.Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47(6):770-790.
18.Duarte RF, Labopin M, Bader P, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: cur- rent practice in Europe, 2019. Bone Marrow Transplant. 2019;54(10):1525-1552.
19. Sullivan KM, Majhail NS, Bredeson C, et al. Systemic sclerosis as an indication for autol- ogous hematopoietic cell transplantation: position statement from the american socie- ty for blood and marrow transplantation. Biol Blood Marrow Transplant. 2018;24(10): 1961-1964.
20. Passweg JR, Baldomero H, Bader P, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2018;53(9):1139-1148.
21.Burt RK, Oliveira MC, Shah SJ, et al. Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. Lancet. 2013;381 (9872):1116-1124.
22. Farge D, Arruda LC, Brigant F, et al. Long- term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients. J Hematol Oncol. 2017;10(1):21.
23. Oliveira MC, Labopin M, Henes J, et al. Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transplant. 2016;51(4):501-505.
24. Ayano M, Tsukamoto H, Mitoma H, et al. CD34-selected versus unmanipulated autol- ogous haematopoietic stem cell transplanta- tion in the treatment of severe systemic scle- rosis: a post hoc analysis of a phase I/II clin- ical trial conducted in Japan. Arthritis Res Ther. 2019;21(1):30.
25. Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643-1656.
26. Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell trans- plantation for autoimmune diseases. Bone Marrow Transplant. 2005;35(9):869-879.
27.Saccardi R, Tyndall A, Coghlan G, et al. Consensus statement concerning cardiotox- icity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant. 2004;34(10):877- 881.
28. Mousseaux E, Agoston-Coldea L, Marjanovic Z, et al. Left ventricle replace- ment fibrosis detected by CMR associated with cardiovascular events in systemic scle- rosis patients. J Am Coll Cardiol. 2018;71(6): 703-705.
29. Mueller KA, Mueller, II, Eppler D, et al. Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS One. 2015;10(5):e0126707.
30. Burt RK, Shah SJ, Gheorghiade M, Ruderman E, Schroeder J. Hematopoietic stem cell transplantation for systemic sclero- sis: if you are confused, remember: "it is a matter of the heart". J Rheumatol. 2012;39(2):206-209.
31.Krumm P, Mueller KA, Klingel K, et al. Cardiovascular magnetic resonance patterns of biopsy proven cardiac involvement in systemic sclerosis. J Cardiovasc Magn Reson. 2016;18(1):70.
32.Farge D, Burt RK, Oliveira MC, et al. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant. 2017;52(11):1495-1503.
33. Keever-Taylor CA, Heimfeld S, Steinmiller KC, et al. Manufacture of autologous CD34(+) selected grafts in the NIAID-spon- sored HALT-MS and SCOT multicenter clin- ical trials for autoimmune diseases. Biol Blood Marrow Transplant. 2017;23(9):1463- 1472.
34. McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial out- comes. Blood. 2002;100(5):1602-1610.
haematologica | 2021; 106(2)
383